Taiwan · Delayed Price · Currency is TWD Bioray Biotech Statistics
Total Valuation
Bioray Biotech has a market cap or net worth of TWD 606.50 million. The enterprise value is 447.87 million.
| Market Cap | 606.50M |
| Enterprise Value | 447.87M |
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioray Biotech has 29.59 million shares outstanding. The number of shares has decreased by -11.42% in one year.
| Current Share Class | 29.59M |
| Shares Outstanding | 29.59M |
| Shares Change (YoY) | -11.42% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 11.20% |
| Owned by Institutions (%) | n/a |
| Float | 13.63M |
Valuation Ratios
The trailing PE ratio is 18.81.
| PE Ratio | 18.81 |
| Forward PE | n/a |
| PS Ratio | 2.72 |
| PB Ratio | 1.34 |
| P/TBV Ratio | 1.34 |
| P/FCF Ratio | 8.51 |
| P/OCF Ratio | 8.47 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.28, with an EV/FCF ratio of 6.28.
| EV / Earnings | 13.89 |
| EV / Sales | 2.01 |
| EV / EBITDA | 7.28 |
| EV / EBIT | 11.82 |
| EV / FCF | 6.28 |
Financial Position
The company has a current ratio of 7.85, with a Debt / Equity ratio of 0.10.
| Current Ratio | 7.85 |
| Quick Ratio | 6.05 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.75 |
| Debt / FCF | 0.65 |
| Interest Coverage | 58.66 |
Financial Efficiency
Return on equity (ROE) is 7.38% and return on invested capital (ROIC) is 10.07%.
| Return on Equity (ROE) | 7.38% |
| Return on Assets (ROA) | 4.39% |
| Return on Invested Capital (ROIC) | 10.07% |
| Return on Capital Employed (ROCE) | 7.64% |
| Weighted Average Cost of Capital (WACC) | 5.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.16 |
Taxes
In the past 12 months, Bioray Biotech has paid 8.99 million in taxes.
| Income Tax | 8.99M |
| Effective Tax Rate | 21.80% |
Stock Price Statistics
The stock price has decreased by -7.33% in the last 52 weeks. The beta is 0.22, so Bioray Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -7.33% |
| 50-Day Moving Average | 22.74 |
| 200-Day Moving Average | 23.35 |
| Relative Strength Index (RSI) | 37.56 |
| Average Volume (20 Days) | 16,059 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bioray Biotech had revenue of TWD 222.73 million and earned 32.25 million in profits. Earnings per share was 1.09.
| Revenue | 222.73M |
| Gross Profit | 105.94M |
| Operating Income | 37.90M |
| Pretax Income | 41.24M |
| Net Income | 32.25M |
| EBITDA | 61.49M |
| EBIT | 37.90M |
| Earnings Per Share (EPS) | 1.09 |
Balance Sheet
The company has 204.92 million in cash and 46.29 million in debt, with a net cash position of 158.63 million or 5.36 per share.
| Cash & Cash Equivalents | 204.92M |
| Total Debt | 46.29M |
| Net Cash | 158.63M |
| Net Cash Per Share | 5.36 |
| Equity (Book Value) | 453.01M |
| Book Value Per Share | 15.31 |
| Working Capital | 278.94M |
Cash Flow
In the last 12 months, operating cash flow was 71.64 million and capital expenditures -369,000, giving a free cash flow of 71.27 million.
| Operating Cash Flow | 71.64M |
| Capital Expenditures | -369,000 |
| Depreciation & Amortization | 23.59M |
| Net Borrowing | -45.75M |
| Free Cash Flow | 71.27M |
| FCF Per Share | 2.41 |
Margins
Gross margin is 47.56%, with operating and profit margins of 17.01% and 14.48%.
| Gross Margin | 47.56% |
| Operating Margin | 17.01% |
| Pretax Margin | 18.52% |
| Profit Margin | 14.48% |
| EBITDA Margin | 27.61% |
| EBIT Margin | 17.01% |
| FCF Margin | 32.00% |
Dividends & Yields
Bioray Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 11.42% |
| Shareholder Yield | 11.42% |
| Earnings Yield | 5.32% |
| FCF Yield | 11.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |